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Abstract
Osteolytic metastases due to breast cancer are serious events.
The interactions between breast cancer cells with the micro-
environment of bone have been thought to provide an ideal milieu
for cancer cells.  Recent data now indicate that migration of breast
cancer cells into bone and their subsequent growth into
metastases depends upon the interaction of the receptor activator
of NF-κB ligand (RANKL) with its receptor RANK.
Bone metastases represent a frequent and severe
complication of advanced breast cancer, and are associated
with pathological fractures, intractable pain, and reduced
quality of life. Most skeletal metastases due to breast cancer
are osteolytic with histological evidence of an increased
number and activity of bone-resorbing osteoclasts [1]. That
osteoclasts are actively involved in tumour-induced skeletal
destruction has been noted for decades, and a vicious circle
has been suggested (Figure 1). Tumour cells activate
osteoclasts by producing the putative ‘osteoclast activating
factor’. Osteoclasts in turn resorb bone and release factors
embedded in the bone matrix, including parathyroid hormone-
related peptide (PTHrP), IL-6, and transforming growth factor
(TGF)-β, which serve as tumour survival factors [1].
A major breakthrough in bone cell biology was the identifi-
cation of receptor activator of NF-κB ligand (RANKL), the
stem cell factor for osteoclasts [2,3]. RANKL, which is
abundantly produced by osteoblasts, stimulates osteoclastic
lineage commitment, promotes cellular maturation and
functions, and prolongs survival, which together enhance
bone resorption [3]. RANKL binds to RANK, a member of the
tumour necrosis factor receptor superfamily that is expressed
on osteoclastic lineage cells [2,3]. The effects of RANKL are
counter-balanced by the endogenous decoy receptor
osteoprotegerin (OPG), also produced by osteoblasts [4].
Alterations of the RANKL/OPG balance have been implicated
in a spectrum of skeletal diseases characterised by excessive
osteoclastic activity, including osteoporosis, rheumatoid
arthritis, and bone metastases.
Earlier studies suggested that RANKL may be the long
sought-after osteoclast activating factor, the critical factor
expressed by breast cancer cells that functions as the stem
cell factor for osteoclasts (Figure 1) [5]. When challenged by
PTHrP, the human breast cancer cell line MCF-7 expressed
RANKL, enhanced osteoclastic activity, and caused skeletal
lesions and hypercalcemia after injection into mice [5].
Another human breast cancer cell line, MDA-MB-231, spon-
taneously expressed RANKL and grew bone metastases
when transferred into susceptible mice [6]. Of note, skeletal
lesions in these mice were reduced after blockade of RANKL
by an OPG analogue [6]. These studies indicated that a local
increase of the RANKL-to-OPG ratio is key for skeletal growth
of breast cancer metastases and a potential target for
therapeutic intervention. Other local factors released from bone
matrix by osteoclasts or directly produced by osteoblasts, such
as PTHrP, IL-6, TGF-β and TGF superfamily members as well
as activators and inhibitors of the Wnt signalling pathway, can
directly modulate tumour biology of skeletal metastases. This
involves direct receptor-mediated effects and paracrine effects
converging at the RANKL/OPG level.
The RANKL/RANK pathway may direct breast cancer cells to
preferentially migrate into bone, the crucial requirement and
initial step for skeletal metastasis. Epithelial cells from normal
mammary glands express RANK, and RANKL-RANK signal-
ling is required for the development of lactating mammary
glands during pregnancy [7]. Both RANKL- and RANK-
deficient mice lack lactating mammary glands and cannot
feed their off-spring [7]. Based on high constitutive RANK
expression in breast cancer specimens and cell lines, recent
data now indicate that the RANK expression status of cancer
cells determines whether tumours predominantly migrate into
bone, where the corresponding ligand RANKL is abundantly
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expressed [8]. The correlation of high RANK expression with
osteotropism in murine models was demonstrated across
diverse tumour cell types, including breast cancer and
melanoma [8]. Blocking RANKL-RANK signalling in these
mice by OPG administration reduced the skeletal tumour
burden by 50% and prevented tumour-induced paralysis [8].
What are the clinical lessons to be learned from these
discoveries? The ménage à trois of breast cancer cells,
osteoblasts, and osteoclasts is linked through the RANKL/
RANK/OPG system, which explains why tumour cells home
to bone and later on destroy it. It will be important to know
whether high-risk patients for skeletal metastases can be
identified based on high RANK expression in their primary
breast tumours. Currently, women with skeletal metastases
due to breast cancer are treated by chemotherapy, radio-
therapy, and intravenous bisphosphonates, or combinations
thereof. Of these, bisphosphonates inhibit certain osteoclast
functions and promote osteoclast apoptosis. Recently, a fully
human monoclonal antibody against RANKL (denosumab)
has been developed and is currently being evaluated in
clinical trials. Denosumab interferes with RANK signalling by
blocking RANKL and, just like OPG, preventing RANK
activation. Denosumab protected against bone loss in
postmenopausal women with low bone mass based on
biochemical markers of bone turnover and measurements of
bone mineral density [9]. Moreover, RANKL inhibition also
suppressed biochemical markers of bone turnover and
skeletal-related events such as fractures, spinal cord
compression, or the need to perform surgery or radiotherapy
in women with breast cancer [10]. Long-term data on
denosumab will show whether our detailed knowledge of
bone cell biology and the RANKL/RANK pathway can be
translated to prevent skeletal migration and metastases in
women suffering from breast cancer.
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Figure 1
Breast cancer-bone interactions in skeletal metastasis using the
receptor activator of NF-κB ligand (RANKL)/RANK pathway.
Expression of RANK enables breast cancer cells to migrate to bone
where the cognate ligand RANKL is abundantly expressed by
osteoblasts. Some tumour cells express RANKL, whereas others
further enhance RANKL expression by cell-to-cell contact of tumour
cells with osteoblastic lineage cells. This enables breast cancer cells
to enter a vicious circle where they stimulate bone-destroying
osteoclasts that express RANK (first loop). Bone degradation by
osteoclasts creates further space for expansive tumour growth within
the bone microenvironment and releases a variety of growth factors
and cytokines that have been deposited by osteoblasts, including
parathyroid hormone-related peptide (PTHrP), IL-6, and transforming-
growth factor (TGF)-β, and that serve as tumour survival factors
(second loop). OAF, osteoclast activating factor.Page 3 of 3
(page number not for citation purposes)
Bekker PJ; AMG 162 Bone Loss Study Group: Denosumab in
postmenopausal women with low bone mineral density. N
Engl J Med 2006, 354:821-831.
10. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P,
Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, et al.: Ran-
domized active-controlled phase II study of denosumab effi-
cacy and safety in patients with breast cancer-related bone
metastases. J Clin Oncol 2007, 25:4431-4437.
Available online http://breast-cancer-research.com/content/10/1/101